Dr. Mark Stolowitz joins Visicell as Chief Science Officer
Visicell is proud to announce the newest addition to our stellar executive team. After retiring in May of 2019 from the Canary Center at Stanford for Cancer Early Detection, Department of Radiology, Stanford University School of Medicine as the Deputy Director for Operations, Dr. Mark Stolowitz had agreed to joined Visicell Medical Inc. as Chief Science Officer starting in March, 2021.
A seasoned scientific leader with over 35 years of experience conceptualizing and developing innovative life sciences research tools, Mark is acknowledged for creating technology platforms and developing intellectual property to facilitate new business segments and startup ventures, realize new market opportunities and create mergers and acquisitions opportunities. Over the course of 20 years, Mark served as either Chief Executive Officer or Chief Technology Officer in five start-up companies in the life sciences research tools industry. A prolific innovator, he has been issued 47 United States Patents related to Bioconjugation, Protein Chromatography, Protein Immobilization, Nucleic Acid Immobilization, Protein Biochips, SPR Biosensors, and Protein Sequencing.
-Visicell Medical Team